Moderna Inc. (MRNA) recorded another quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled manufacturing contract. Goldman Sachs (GS) US Biotechnology Analyst Salveen Richter explains on "Bloomberg Markets."

Bloomberg videos, provided by MT Newswires